Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity.

about

Mechanisms and Therapy for Cancer Metastasis to the Brain.

P2860

Q54950354-890BF37A-949D-4E23-A602-C7BE37FB75B2

P2860

Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity.

Item

http://www.wikidata.org/entity/Q47133946

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Afatinib Therapy for Brain Met ...... Development of Hepatotoxicity.

@en

Afatinib Therapy for Brain Met ...... Development of Hepatotoxicity.

@nl

type

Item

label

Afatinib Therapy for Brain Met ...... Development of Hepatotoxicity.

@en

Afatinib Therapy for Brain Met ...... Development of Hepatotoxicity.

@nl

prefLabel

Afatinib Therapy for Brain Met ...... Development of Hepatotoxicity.

@en

Afatinib Therapy for Brain Met ...... Development of Hepatotoxicity.

@nl

P1476

Afatinib Therapy for Brain Met ...... Development of Hepatotoxicity

@en

P2093

Akimasa Sekine

http://www.w3.org/2001/XMLSchema#string

Koji Okudela

http://www.w3.org/2001/XMLSchema#string

Satoshi Ikeda

http://www.w3.org/2001/XMLSchema#string

Tae Iwasawa

http://www.w3.org/2001/XMLSchema#string

Takashi Ogura

http://www.w3.org/2001/XMLSchema#string

Terufumi Kato

http://www.w3.org/2001/XMLSchema#string

Tomohisa Baba

http://www.w3.org/2001/XMLSchema#string

Yumie Yamanaka

http://www.w3.org/2001/XMLSchema#string

P2860

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.

Multimodality management of non-small cell lung cancer patients with brain metastases.

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.

Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer.

Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development.

Tolerability and efficacy of afatinib at a low starting dosage in 10 elderly or low performance status patients with advanced refractory non-small-cell lung cancer.

P304

2895-2898

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.2169/INTERNALMEDICINE.8638-16

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hideaki Yamakawa

P577

2017-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28943548

http://www.w3.org/2001/XMLSchema#string

P921

hepatotoxicity

P932

5709634

http://www.w3.org/2001/XMLSchema#string

Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity.

about

P2860

P2860

Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932